TNFRSF9 and cancer: 4-1BB, the counterreceptor for 4-1BBL is an important target for immunotherapeutic approaches and the agonistic 4-1BB antibodies utomilumab and urelumab are being investigated to boost T cell activation in the setting of various cancer entities28,29.